Want to contact Science Speaks? You can reach us by filling out the form below, or by emailing raziz AT idsociety DOT org. (Replace AT with @ and DOT with a dot.)
HIV
When viral suppression didn’t last, lowering barriers to HIV treatment and care made a difference
The goals of controlling HIV sound like a straight forward series of three consecutive steps, one following another, when discussed in global and domestic epidemic-ending plans. […]
Tuberculosis
New TB drug approval a milestone, all agree — with caveats, some add
The announcement Wednesday of U.S. Food and Drug Administration approval of pretomanid, a new tuberculosis drug that has been part of a ground-breaking treatment regimen against […]
Research & Development
STREAM Trial: Nine-month regimen for drug-resistant tuberculosis brings “promising cure rates”
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
Policy
Toolkit supports data gathering to aid children often overlooked
The following is a guest post by Jacqueline Hellen and Lisa Parker of MEASURE Evaluation While programs in low- and middle-income countries seek to support children […]